Status:
COMPLETED
Efficacy of Pulmozyme® on Arterial Recanalization in Post-thrombectomy Patients Managed for Ischemic Stroke (NETs-target)
Lead Sponsor:
Fondation Ophtalmologique Adolphe de Rothschild
Conditions:
Ischemic Stroke
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The functional prognosis of patients with ischaemic stroke treated by thrombolysis and thrombectomy is associated with complete reperfusion of the occluded artery defined by an mTICI 2C or 3 score at ...
Eligibility Criteria
Inclusion
- Ischemic stroke by proximal intracranial occlusion (internal carotid artery, middle cerebral artery in its M1 or M2 segment) isolated from the anterior circulation eligible for cerebral thrombectomy.
- Transferred to the NRI block for a cerebral thrombectomy.
- Treated by thrombolysis intravenous (Aleplase or Tenecteplase) as recommanded by European stroke organisation
- With DWI-ASPECT score\>5 to MRI
Exclusion
- Pregnant or breastfeeding woman
- Known allergy to Dornase alfa or one of its excipients.
Key Trial Info
Start Date :
August 19 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 18 2025
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT04785066
Start Date
August 19 2022
End Date
August 18 2025
Last Update
September 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Fondation Adolphe de Rothschild
Paris, Paris, France, 75019